Healthcare ratings roundup

• Anthera Pharmaceuticals (OTC:ANTH) initiated with Buy rating and $10 (180% upside) price target by H.C. Wainwright.
• Ultragenyx Pharmaceutical (NASDAQ:RARE) initiated with Overweight rating and $70 (31% upside) price target by Piper Jaffray.
• Eiger Biopharmaceuticals (NASDAQ:EIGR) initiated with Outperform rating and $34 (85% upside) price target by Oppenheimer.
• Intercept Pharmaceuticals (NASDAQ:ICPT) initiated with Sell rating and $58 (61% downside risk) price target by Cantor Fitzgerald.
• Juno Therapeutics (NASDAQ:JUNO) initiated with Equal Weight rating and $48 (73% upside) price target by Barclays.
• Kite Pharma (NASDAQ:KITE) initiated with Equal Weight rating and $58 (21% upside) price target by Barclays.
• Endologix (NASDAQ:ELGX) upgraded to Outperform from Market Perform by BMO Capital. Price target raised to $16 (14% upside) from $11.50.
• Achillion Pharmaceuticals (NASDAQ:ACHN) upgraded to Outperform from Market Perform with a $13 (42% upside) price target by JMP Securities.
• Humana (NYSE:HUM) downgraded to Neutral from Overweight by JPMorgan. Price target lowered to $150 (8% downside risk) from $196.
• Ilumina (NASDAQ:ILMN) downgraded to Underweight from Equal Weight by Morgan Stanley. Price target lowered to $110 (22% downside risk) from $130.
• T2 Biosystems (NASDAQ:TTOO) downgraded to Sell from Buy by BTIG Research. Price target lowered to $4 (26% downside risk) from $12.
• Juno Therapeutics (JUNO) downgraded to Neutral from Overweight by JPMorgan. Price target lowered to $39 (40% upside) from $63.
• Depomed (DEPO) downgraded to Neutral from Buy with $20 (6% upside) price target by UBS.
• Esperion Therapeutics (NASDAQ:ESPR) downgraded to Hold from Buy by WallachBeth.